Bridge Biotherapeutics, Boehringer Ingelheim cancel agreement to develop BBT-877 for idiopathic pulmonary fibrosis Read more
Boehringer Ingelheim and Click Therapeutics join hands for CT-155, digital therapeutic for schizophrenia Read more